Biotech Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests
NewsDealsSocialBlogsVideosPodcasts
Korsana Raises $150M in Series A to Develop Next‑gen Alzheimer’s Antibody
Series ABioTechHealthcareVenture Capital

Korsana Raises $150M in Series A to Develop Next‑gen Alzheimer’s Antibody

•February 18, 2026
•Feb 18, 2026
0

Participants

Korsana Biosciences

Korsana Biosciences

company

Deal Summary

Korsana, a biotech focused on Alzheimer’s disease, announced a $150 million Series A funding round to advance its next‑generation amyloid‑targeting antibody. The capital will fund clinical development and expansion of its pipeline. Investor identities were not disclosed.

0

Comments

Want to join the conversation?

Loading comments...